Latest Blog Posts
Search
Sort Results
Filter by Programming
Filter by Specific Population
Filter by Topic
- Organ and body health (41)
- Reproductive and maternal health (14)
- Disease progression (13)
- Infections and cancers (10)
- Emotional health (8)
- Prevention interventions (6)
- Social determinants of health (4)
- Testing and diagnosis (3)
- Harm reduction and substance use (2)
- Healthy living (2)
- Government and community strategies (1)
- Transmission and risk (1)
Filter by Infection
Filter by Resource Category
- Research summary (remove)
Search results
Current filters: HIV, Treatment, Research summary
208 search results
- Dovato (dolutegravir + 3TC) in initial HIV treatment
-
From TreatmentUpdate 233
2019, CATIE
Research summary - Webpage - Switching to Dovato (dolutegravir + 3TC) from a TAF-based regimen
-
From TreatmentUpdate 233
2019, CATIE
Research summary - Webpage - Some issues to consider with Dovato (dolutegravir + 3TC)
-
From TreatmentUpdate 233
2019, CATIE
Research summary - Webpage - More dual HIV regimens are coming
-
From TreatmentUpdate 233
2019, CATIE
Research summary - Webpage - Decreasing the risk of neural tube defects with dolutegravir
-
From TreatmentUpdate 233
2019, CATIE
Research summary - Webpage - Dovato approved in Canada for HIV treatment
-
2019, CATIE
Research summary - Webpage - Gene therapy—CRISPR starts to move forward against HIV
-
From TreatmentUpdate 232
2019, CATIE
Research summary - Webpage - Will gene therapy for HIV cause financial toxicity?
-
From TreatmentUpdate 232
2019, CATIE
Research summary - Webpage - B.C. study finds that providing ART and methadone in the same facility helps adherence
-
2019, CATIE
Research summary - Webpage - International success stories in HIV prevention: What can Canada learn?
-
From Prevention in Focus - Fall 2019
2019, CATIE
Research summary - Webpage
